Clinical trial demonstrates improved antitumor activity in Ewing sarcoma patients with metastasis, suggesting new treatment options.
Ewing sarcoma is a highly malignant neoplasm of bone or soft tissues that is predominantly seen in adolescents and young adults. Patients with recurrent and metastasis have poor survival despite aggressive treatment. In Ewing sarcoma, EWS–FLI-1 translocation has been identified as a biomarker for Poly-ADP ribose Polymerase inhibitor (PARPi) sensitivity and olaparib has been shown to enhance the antitumor activity of chemotherapy agents like temozolomide, irinotecan, and trabectedin. We tried the combination of olaparib and temozolomide in an adult patient of Ewing sarcoma who had metastatic disease, and after 4 months of treatment, he showed excellent response to treatment.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: